Research graph
References from Organ-specific liquid biopsy in lung cancer: the emerging role of exhaled breath condensate. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2021 · External reference
Reduced lung-cancer mortality with low-dose computed tomographic screening
10.1056/nejmoa1102873 · 2011 · External reference
Liquid biopsy in lung cancer
10.1183/20734735.0051-2025 · 2025 · External reference
Early detection of lung cancer: a review of innovative milestones and techniques
10.3390/jcm14217812 · 2025 · External reference
Tracking the evolution of non-small-cell lung cancer
10.1056/nejmoa1616288 · 2017 · External reference
Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
10.1016/j.jtho.2021.06.017 · 2021 · External reference
Integrating genomic features for non-invasive early lung cancer detection
10.1038/s41586-020-2140-0 · 2020 · External reference
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
10.1038/nature22364 · 2017 · External reference
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer
10.1093/annonc/mdw037 · 2016 · External reference
The biology and management of non-small cell lung cancer
10.1038/nature25183 · 2018 · External reference
Exhaled breath condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel
10.1016/j.lungcan.2022.04.013 · 2022 · External reference
Brief report on the detection of the EGFR T790M mutation in exhaled breath condensate from lung cancer patients
10.1016/j.jtho.2018.04.033 · 2018 · External reference
Direct detection of early-stage cancers using circulating tumor DNA
10.1126/scitranslmed.aan2415 · 2017 · External reference
Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection
10.1038/s41571-018-0058-3 · 2018 · External reference
Origins, structures, and functions of circulating DNA in oncology
10.1007/s10555-016-9629-x · 2016 · External reference
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
10.1056/nejmoa1409405 · 2014 · External reference
Clonal hematopoiesis and nonhematologic disorders
2020 · External reference
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
10.1038/nm.3519 · 2014 · External reference
Exhaled breath condensate: methodological recommendations and unresolved questions
10.1183/09031936.05.00029705 · 2005 · External reference
Screening for lung cancer: US preventive services task force recommendation statement
10.1001/jama.2021.1117 · 2021 · External reference
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
10.1126/scitranslmed.aaf6219 · 2016 · External reference
Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline
10.1016/j.prro.2017.04.014 · 2017 · External reference
Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review
10.1016/j.radonc.2013.01.004 · 2013 · External reference
Biomarkers in lung cancer screening: achievements, promises, and challenges
10.1016/j.jtho.2018.11.023 · 2019 · External reference
Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing
10.18632/oncotarget.15233 · 2017 · External reference
Concordance in molecular genetic analysis of tumour tissue, plasma, and exhaled breath condensate samples from lung cancer patients
10.1088/1752-7163/ab739b · 2020 · External reference
Hotspot mutations detectable by next-generation sequencing in exhaled breath condensates from patients with lung cancer
10.21873/anticanres.12897 · 2018 · External reference
Assessment of exhaled breath condensate for ALK, RET, ROS1, and NTRK1 fusion transcript detection in NSCLC: comparison with tissue and liquid biopsy samples
10.1111/1759-7714.15513 · 2025 · External reference
Conversion of specific lncRNAs to biomarkers in exhaled breath condensate samples of patients with advanced stage non-small-cell lung cancer
10.3389/fgene.2023.1200262 · 2023 · External reference
Feasibility of detecting non-small cell lung cancer using exhaled breath condensate metabolomics
10.1088/1752-7163/adab88 · 2025 · External reference
Volatile signature for the early diagnosis of lung cancer
10.1088/1752-7155/10/1/016007 · 2016 · External reference
Genome-wide cell-free DNA fragmentation in patients with cancer
10.1038/s41586-019-1272-6 · 2019 · External reference
Enhanced detection of circulating tumor DNA by fragment size analysis
10.1126/scitranslmed.aat4921 · 2018 · External reference
Liquid biopsies come of age: towards implementation of circulating tumour DNA
10.1038/nrc.2017.7 · 2017 · External reference
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
10.1016/j.annonc.2020.02.011 · 2020 · External reference
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments
10.1073/pnas.1508736112 · 2015 · External reference
Exhaled breath condensate: an update
10.1016/j.iac.2018.06.002 · 2018 · External reference
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
10.1038/s41591-019-0652-7 · 2019 · External reference
Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin
10.1016/j.cell.2015.11.050 · 2016 · External reference
Detection and localization of surgically resectable cancers with a multi-analyte blood test
10.1126/science.aar3247 · 2018 · External reference
Reduced lung-cancer mortality with volume CT screening in a randomized trial
10.1056/nejmoa1911793 · 2020 · External reference
Probability of cancer in pulmonary nodules detected on first screening CT
10.1056/nejmoa1214726 · 2013 · External reference
10.1097/jto.0b013e318290868f
10.1097/jto.0b013e318290868f · 2013 · External reference
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling
10.1158/2159-8290.cd-17-0716 · 2017 · External reference
Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring
10.1200/edbk-25-481114 · 2025 · External reference
Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review
10.1200/jco.2017.76.8671 · 2018 · External reference
European position statement on lung cancer screening
10.1016/s1470-2045(17)30861-6 · 2017 · External reference
Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion
10.1136/esmoopen-2019-000577 · 2019 · External reference
The 2021 US preventive services task force recommendation on lung cancer screening: the more things stay the same
10.1001/jamaoncol.2020.8376 · 2021 · External reference
